MedTrace Logo

A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

NCT05751486 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-03-02

No results posted yet for this study

Summary

The purpose of this phase I clinical study was to evaluate the safety and tolerability of JS001sc monotherapy and combination with gemcitabine and cisplatin (GP) in patients with Advanced nasopharyngeal carcinoma.

Conditions

  • Advanced Nasopharyngeal Carcinoma

Interventions

BIOLOGICAL

Toripalimab injection(subcutaneous)/JS001sc

JS001sc Q3W combination with gemcitabine and cisplatin.

BIOLOGICAL

Toripalimab injection(subcutaneous)/JS001sc

JS001sc long period combination with gemcitabine and cisplatin.

BIOLOGICAL

Toripalimab /JS001

JS001 IV (if applicable) .

BIOLOGICAL

Toripalimab injection(subcutaneous)/JS001sc

Additional cohort (if applicable)

Sponsors & Collaborators

  • Shanghai Junshi Bioscience Co., Ltd.

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-21
Primary Completion
2023-12-30
Completion
2025-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05751486 on ClinicalTrials.gov